Market LIVE
Published markets; coverage varies by country
Product profile · United States

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

 ·  Patent Litigation & Settlement History ↓

IngredientCEFEPIME HYDROCHLORIDE
Application typeNDA
Application050821
Product001
Dosage formINJECTABLE
RouteINJECTION
StrengthEQ 1GM BASE/VIAL
Approval date2010-05-06
Marketing statusPrescription
Status event—
ApplicantB BRAUN
Product source

Current GenericRadar decision

Year2010
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeAPPROVAL_DATE
Anchor date2010-05-06
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

APPROVAL_YEAR_FALLBACK: current product-specific evidence does not establish a DS/DS-equivalent or all-indication exclusivity anchor. Evidence limits: complete comparison of unverified ANDA candidates against original RLD documents remains incomplete; absence of generics is not established; complete historical patent/exclusivity collection remains incomplete.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
065369 / 002FINAL_APPROVAL · FINAL_APPROVED2007-06-18—HOSPIRA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
065441 / 001FINAL_APPROVAL · FINAL_APPROVED2008-03-20—ACS DOBFAR SPANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
090291 / 002FINAL_APPROVAL · FINAL_APPROVED2010-12-21—CHARTWELL RX SCIENCES LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
202268 / 001FINAL_APPROVAL · FINAL_APPROVED2012-07-30—HOSPIRA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
203704 / 002FINAL_APPROVAL · FINAL_APPROVED2016-02-01—QILU ANTIBIOTICS PHARMACEUTICAL CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
091048 / 001FINAL_APPROVAL · FINAL_APPROVED2017-01-04—SAGENT PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212721 / 001FINAL_APPROVAL · FINAL_APPROVED2020-07-21—ASTRAL STERITECH PVT LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214402 / 001FINAL_APPROVAL · FINAL_APPROVED2024-05-22—HIKMA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 8 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
065369 / 002HOSPIRA INCFINAL_APPROVAL · FINAL_APPROVED2007-06-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
065441 / 001ACS DOBFAR SPAFINAL_APPROVAL · FINAL_APPROVED2008-03-20 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
090291 / 002CHARTWELL RX SCIENCES LLCFINAL_APPROVAL · FINAL_APPROVED2010-12-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
202268 / 001HOSPIRA INCFINAL_APPROVAL · FINAL_APPROVED2012-07-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
203704 / 002QILU ANTIBIOTICS PHARMACEUTICAL CO LTDFINAL_APPROVAL · FINAL_APPROVED2016-02-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
091048 / 001SAGENT PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2017-01-04 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212721 / 001ASTRAL STERITECH PVT LTDFINAL_APPROVAL · FINAL_APPROVED2020-07-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214402 / 001HIKMA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2024-05-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.